Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ANI Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ ANIP opened at $53.35 on Friday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12-month low of $52.00 and a 12-month high of $70.81. The firm’s 50-day moving average price is $57.93 and its 200-day moving average price is $60.09. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -97.00 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.05 earnings per share. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Global Alpha Capital Management Ltd. raised its stake in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after acquiring an additional 9,500 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $228,000. Thompson Siegel & Walmsley LLC grew its holdings in ANI Pharmaceuticals by 17.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after purchasing an additional 34,416 shares during the last quarter. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in ANI Pharmaceuticals by 15.4% in the second quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company’s stock worth $9,985,000 after purchasing an additional 20,900 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ANIP shares. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Piper Sandler assumed coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.